356 related articles for article (PubMed ID: 25201123)
1. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
Juraschek SP; Kovell LC; Miller ER; Gelber AC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
[TBL] [Abstract][Full Text] [Related]
3. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
[TBL] [Abstract][Full Text] [Related]
5. Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.
Kwok TSH; Kuriya B; Hawker G; Li P; Choy G; Widdifield J
Arthritis Care Res (Hoboken); 2023 Dec; 75(12):2463-2471. PubMed ID: 37248652
[TBL] [Abstract][Full Text] [Related]
6. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
Quilisadio JEC; Salido EO; Penserga EG
Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
[TBL] [Abstract][Full Text] [Related]
7. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
[TBL] [Abstract][Full Text] [Related]
8. Serum urate goal attainment and associated factors in Chinese gout patients.
Guo G; Dong C; Yin R; Yang Y; Zhao R; Wang Y; Guo J; Zhou W; Lu G
Psychol Health Med; 2020 Sep; 25(8):931-939. PubMed ID: 31870173
[TBL] [Abstract][Full Text] [Related]
9. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
Huang IJ; Liew JW; Morcos MB; Zuo S; Crawford C; Bays AM
Rheumatol Int; 2019 Sep; 39(9):1637-1641. PubMed ID: 31147732
[TBL] [Abstract][Full Text] [Related]
10. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
12. Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Ann Rheum Dis; 2021 Nov; 80(11):1483-1490. PubMed ID: 34158371
[TBL] [Abstract][Full Text] [Related]
13. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
[TBL] [Abstract][Full Text] [Related]
14. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
Chen-Xu M; Yokose C; Rai SK; Pillinger MH; Choi HK
Arthritis Rheumatol; 2019 Jun; 71(6):991-999. PubMed ID: 30618180
[TBL] [Abstract][Full Text] [Related]
15. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
[TBL] [Abstract][Full Text] [Related]
17. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
18. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Jackson RL; Hunt B; MacDonald PA
BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
[TBL] [Abstract][Full Text] [Related]
20. Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry.
Do H; Choi HJ; Choi B; Son CN; Kim SH; Choi SR; Kim JH; Kim MJ; Shin K; Kim HO; Song R; Lee SW; Ahn JK; Lee SG; Lee CH; Son KM; Moon KW
Sci Rep; 2023 Nov; 13(1):20511. PubMed ID: 37993515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]